{{Rsnum
|rsid=3797177
|Gene=SRD5A1
|Chromosome=5
|position=6666971
|Orientation=minus
|GMAF=0.2231
|Gene_s=SRD5A1
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 75.2 | 22.1 | 2.7
| HCB | 55.5 | 39.4 | 5.1
| JPT | 66.4 | 29.2 | 4.4
| YRI | 36.7 | 49.0 | 14.3
| ASW | 38.6 | 47.4 | 14.0
| CHB | 55.5 | 39.4 | 5.1
| CHD | 67.0 | 25.7 | 7.3
| GIH | 86.1 | 13.9 | 0.0
| LWK | 38.2 | 52.7 | 9.1
| MEX | 82.8 | 15.5 | 1.7
| MKK | 54.5 | 35.9 | 9.6
| TSI | 72.5 | 25.5 | 2.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA}}